Literature DB >> 19076541

Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency.

M Cugno1, A Zanichelli, A G Bellatorre, S Griffini, M Cicardi.   

Abstract

BACKGROUND: Cl-inhibitor (C1-INH) deficiency leads to recurrent attacks of mucocutaneous edema and may be inherited (hereditary angioedema [HAE]) or acquired (acquired angioedema [AAE]), which have the same clinical picture characterized by angioedema involving the skin, gastrointestinal tract, and larynx. Although cutaneous swelling is evident, abdominal angioedema is still a diagnostic challenge and attacks can mimic surgical emergencies. There is currently no laboratory marker for identifying angioedema attacks.
OBJECTIVE: As coagulation and fibrinolysis are activated during angioedema attacks, we assessed if plasma measurements of prothrombin fragment F1 + 2 (marker of thrombin generation) and D-dimer (marker of fibrin degradation) can be useful for the diagnosis of angioedema because of C1-INH deficiency, especially in case of hidden locations as abdominal attacks.
METHODS: In addition to complement, we measured plasma levels of F1 + 2 and D-dimer in 28 patients with C1-INH deficiency during acute attacks and remission, 35 patients without C1-INH deficiency during abdominal colics, and 20 healthy subjects.
RESULTS: Plasma F1 + 2 levels were higher in patients with C1-INH deficiency during remission than in healthy controls (P = 0.001), and further increased during cutaneous and abdominal attacks (P = 0.0001); patients without C1-INH deficiency had normal F1 + 2 levels during abdominal colics. Plasma D-dimer levels were higher in patients with C1-INH deficiency during remission than in controls (P = 0.012) and increased during angioedema attacks, reaching higher levels than in patients without C1-INH deficiency during colics (P = 0.002).
CONCLUSIONS: During acute angioedema attacks, patients with C1-INH deficiency have high prothrombin fragment F1 + 2 and D-dimer levels, the measurement of which may have an important diagnostic value.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19076541     DOI: 10.1111/j.1398-9995.2008.01859.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  23 in total

1.  Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. [corrected]

Authors:  Marco Cicardi
Journal:  Intern Emerg Med       Date:  2010-03-27       Impact factor: 3.397

Review 2.  Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications.

Authors:  Massimo Cugno; Angelo V Marzano; Riccardo Asero; Alberto Tedeschi
Journal:  Intern Emerg Med       Date:  2009-12-01       Impact factor: 3.397

3.  Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts.

Authors:  Marco Cicardi; Paolo Bellis; Giuliano Bertazzoni; Mauro Cancian; Maurizio Chiesa; Paolo Cremonesi; Pietro Marino; Nicola Montano; Claudia Morselli; Francesco Ottaviani; Roberto Perricone; Massimo Triggiani; Andrea Zanichelli
Journal:  Intern Emerg Med       Date:  2013-09-04       Impact factor: 3.397

Review 4.  Angioedema due to C1 inhibitor deficiency in 2010.

Authors:  Marco Cicardi; Andrea Zanichelli
Journal:  Intern Emerg Med       Date:  2010-05-22       Impact factor: 3.397

5.  Pediatric hereditary angioedema due to C1-inhibitor deficiency.

Authors:  Henriette Farkas
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

Review 6.  "Nuts and Bolts" of Laboratory Evaluation of Angioedema.

Authors:  Henriette Farkas; Nóra Veszeli; Erika Kajdácsi; László Cervenak; Lilian Varga
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 7.  Clinical manifestations of hereditary angioedema and a systematic review of treatment options.

Authors:  Mattie Rosi-Schumacher; Sejal J Shah; Timothy Craig; Neerav Goyal
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-04-03

Review 8.  Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2.

Authors:  Lauré M Fijen; Konrad Bork; Danny M Cohn
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-09       Impact factor: 8.667

Review 9.  The Story of Angioedema: from Quincke to Bradykinin.

Authors:  Avner Reshef; Mona Kidon; Iris Leibovich
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 10.817

Review 10.  Biomarkers in Hereditary Angioedema.

Authors:  Grzegorz Porebski; Mateusz Kwitniewski; Avner Reshef
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-09       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.